infohep news

• New Interferon treatment for HBV

  Adding interferon to nucleoside antivirals may improve response for people with chronic hepatitis B

  Liz Highleyman / 8 hours ago

  Adding pegylated interferon to entecavir (Baraclude) led to greater hepatitis B virus (HBV) viral load decline and higher likelihood of serological response in people with HBeAg-positive chronic hepatitis B, as did added interferon after ...

• New Treatment for previous non-responders & relapsers

  Sofosbuvir for hepatitis C works well despite multiple negative predictive factors

  Liz Highleyman / 8 hours ago

  Hepatitis C treatment using sofosbuvir (Sovaldi) is highly effective even for people with multiple factors traditionally associated with poor response. Having four or more negative predictive factors, however, raises the risk of post-treatment relapse, ...

• New Interferon-free regimens

  MK-5172 + MK-8742 demonstrate good early post-treatment response rates

  Liz Highleyman / 8 hours ago

  A combination of two direct-acting antivirals, MK-5172 and MK-8742, with or without ribavirin, led to early post-treatment sustained response rates above 90% for people with genotype 1 hepatitis C virus (HCV), including ...

• Hepatitis delta

  Prolonged pegylated interferon plus tenofovir does not prevent hepatitis delta relapse

  Liz Highleyman / 23 April 2014

  Treating hepatitis B patients with hepatitis delta virus (HDV) co-infection using pegylated interferon plus tenofovir (Viread) for 96 weeks may reduce HDV viral load, but side-effects are frequent and it did not significantly improve ...

• Treatment in liver transplanted

  Three-drug AbbVie combination safe and highly effective in treatment of post-transplant hepatitis C recurrence

  Keith Alcorn / 23 April 2014

  A three-drug combination of direct-acting antivirals developed by AbbVie cured hepatitis C genotype 1 infection in 96% of transplant recipients with recurrent hepatitis C in a small phase II study reported at ...